A clinical trial is any research study that evaluates interventions to prevent, detect, diagnose, or treat a disease or disorder. In a clinical trial, human participants (or groups of participants) are assigned to one or more interventions to assess the results on health outcomes.
Why Are Clinical Trials Important?
Clinical Trials are important in discovering new treatments to prevent, detect, diagnose or treat Narcolepsy. It is the only process to bring new pharmacological drugs and treatments forward for approval to use within the Narcolepsy community. Without the clinical trials, there is a risk that individuals could be given treatments which have no advantage, waste time and could even be harmful to one’s health. If a treatment has no benefit, or has serious side effects, the treatment may not be further developed.
Ongoing Research
Clinical Trial
The ALBA Study for idiopathic hypersomnia (IH)
The investigational drug, TAK-360, is an oral, highly selective orexin 2 receptor (OX2R) agonist. With its potential to improve excessive daytime sleepiness (EDS) and related symptoms through a novel mechanism of action, TAK-360 could offer, if proven effective, a new treatment option for people with IH.
Vibrance-3 clinical study for idiopathic hypersomnia
The Vibrance-3 Study is researching an investigational oral study drug for the potential treatment of excessive daytime sleepiness symptoms. Adults 18-70 years of age with idiopathic hypersomnia are invited to learn more about this important sleep disorder research.
CRYSTAL-1 Study: A Study of ORX750 in Participants with Narcolepsy and Idiopathic Hypersomnia
NOW RECRUITING adults (ages 18-65) with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in the U.S. and Canada.
REVITALYZ Study
REVITALYZ is a phase 3 clinical study looking at the efficacy and safety of a study drug for the treatment of idiopathic hypersomnia in adults.
Vibrance-2 clinical study for narcolepsy type 2
The Vibrance-2 Study is researching an investigational oral study drug for the potential treatment of excessive daytime sleepiness symptoms. Adults 18-70 years of age with narcolepsy type 2 are invited to learn more about this important sleep disorder research.
Impact of Low Sodium Oxybate on Total Sleep Time in Patients with Idiopathic Hypersomnia
Stanford University and Mayo Clinic have partnered to evaluate the efficacy of low sodium oxybate on total sleep time in patients with idiopathic hypersomnia. The comprehensive assessments will yield detailed information about how low sodium oxybate affects sleep, breathing, and other physiological metrics, ultimately enhancing understanding of idiopathic hypersomnia.
Research Study
Development of a narcolepsy patient-reported outcome measure and assessment of its psychometric properties
The University of Sydney needs your help to build and test a new questionnaire so that it measures the real-life impact of narcolepsy.
Validation of the Situational Sleepiness Scale
In efforts to modernize clinical measurements of sleepiness, Stanford physicians partnered with the UK biobank to develop the Situational Sleepiness Scale.
IQVIA Survey and Interviews in Narcolepsy and IH with Xywav
IQVIA is currently looking for adults (≥18 years of age) who have been diagnosed with narcolepsy or IH currently taking Xywav® to take part in a paid research study.